National Healthcare Agreement: PI 10-Prevalence of Type 2 diabetes, 2015
Indicator Attributes
Identifying and definitional attributes | |
Metadata item type:![]() | Indicator |
---|---|
Indicator type:![]() | Progress measure |
Short name:![]() | PI 10- Prevalence of Type 2 diabetes, 2015 |
METEOR identifier:![]() | 559048 |
Registration status:![]() |
|
Description:![]() | The proportion of people who have Type 2 diabetes. |
Indicator set:![]() | National Healthcare Agreement (2015) |
Outcome area:![]() | Prevention Health, Standard 07/07/2010 |
Quality statement:![]() | National Healthcare Agreement: PI 10-Prevalence of Type 2 diabetes, 2015 QS Health, Standard 14/01/2015 |
Collection and usage attributes | |
Computation description:![]() | The National Health Measures Survey component of the 2011–13 Australian Health Survey included a fasting plasma glucose test.
A respondent to the survey is considered to have known diabetes if they had ever been told by a doctor or nurse that they have Type 2 diabetes and:
A respondent to the survey is considered to have newly diagnosed diabetes if they reported no prior diagnosis of diabetes, but had a fasting plasma glucose value greater than or equal to 7.0 mmol/L. Excludes persons who did not fast for 8 hours or more prior to their blood test. Excludes women with gestational diabetes. The data are reported for two age ranges:
Rates are directly age-standardised to the 2001 Australian population. Analysis by remoteness and Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage (IRSD) is based on usual residence of person (based on data availability). Presented as a percentage. 95% confidence intervals and relative standard errors calculated for rates. Note: The type of diabetes for newly diagnosed cases cannot be determined from a fasting plasma glucose or HbA1c test alone. However, it is assumed that the vast majority of newly diagnosed cases would be Type 2. |
---|---|
Computation:![]() | 100 x (numerator/denominator) |
Numerator:![]() | Number of persons aged 18 years and over with known diabetes (Type 2) or newly diagnosed diabetes as determined by a fasting plasma glucose test. For the supplementary measure: number of persons aged 25 years and over with known diabetes (Type 2) or newly diagnosed diabetes as determined by a fasting plasma glucose test. |
Numerator data elements:![]() | |
Denominator:![]() | Population aged 18 year and over. For the supplementary measure: population aged 25 years and over. |
Denominator data elements:![]() | |
Disaggregation:![]() | 2011–12—State and territory, by:
2011–12 (previously supplied)—Nationally, by:
2011-13—State and territory, by Indigenous status (Indigenous only). Some disaggregation may result in numbers too small for publication. |
Disaggregation data elements:![]() | |
Comments:![]() | Most recent data available for 2015 National Healthcare Agreement (NHA) performance reporting: 2011-12 (total population, non-Indigenous: AHS); 2012–13 (Indigenous only: AATSIHS). |
Representational attributes | |
Representation class:![]() | Percentage |
Data type:![]() | Real |
Unit of measure:![]() | Person |
Data source attributes | |
Data sources:![]() | |
Accountability attributes | |
Reporting requirements:![]() | National Healthcare Agreement |
Organisation responsible for providing data:![]() | Australian Bureau of Statistics |
Benchmark:![]() | National Healthcare Agreement: PB c-Better health: reduce the age-adjusted prevalence rate for Type 2 diabetes to 2000 levels (equivalent to a national prevalence rate (for 25 years and over) of 7.1 per cent) by 2023, 2015 |
Further data development / collection required:![]() | Specification: Final, the measure meets the intention of the indicator. |
Source and reference attributes | |
Submitting organisation:![]() | Australian Bureau of Statistics |
Relational attributes | |
Related metadata references:![]() | Supersedes National Healthcare Agreement: PI 10-Prevalence of Type 2 diabetes, 2014
Has been superseded by National Healthcare Agreement: PI 10–Prevalence of Type 2 diabetes, 2016
|